Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUDC-305 in Moderate to Severe Plaque Psoriasis
NCT03675542Phase 1Unknown
- Sponsor
- Aarhus University Hospital
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cudc-305 in plaque psoriasis, sponsored by Aarhus University Hospital. Primary endpoint: Change from baseline in Psoriasis Area and Severity Index at 12 weeks. Status: unknown.
02
Drugs
cudc-305
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03675542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675542.